dabigatran etexilate + clarithromycin

dabigatran etexilate + clarithromycin is a combination regimen consisting of dabigatran etexilate, an oral anticoagulant prodrug that is converted to dabigatran—a competitive and reversible direct thrombin inhibitor—and clarithromycin, a macrolide antibiotic and moderate P-glycoprotein (P-gp) inhibitor[3][2][1]. When administered together, clarithromycin inhibits P-gp-mediated efflux of dabigatran etexilate in the intestine, leading to increased oral bioavailability and systemic exposure of dabigatran (peak plasma concentration and area-under-the-curve increased ~50-60%)[2][1]. This may increase the risk of bleeding due to elevated anticoagulant effect[1][2]. The combination is relevant in patients with indications for both agents, such as atrial fibrillation and concurrent infection, but requires careful monitoring due to significant drug-drug interaction.

Brand names

Pradaxa (dabigatran etexilate)Zeclar (clarithromycin)

Other names

dabigatran etexilateclarithromycin